Showing 8111-8120 of 9427 results for "".
- Dermatologist Launches Website For Anti-MOC Campaignhttps://practicaldermatology.com/news/dermatologist-launches-website-for-anti-moc-campaign/2458817/Aimed at dermatologists who “believe that board certification should be a one time right of passage and that Maintenance of Certification (MOC) is an undue burden,” a new website from Las Vegas dermatologist H. L. Greenberg, MD encourages board certified dermatologists to si
- FDA Approves Cotellic Combined with Zelboraf to Treat Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-cotellic-combined-with-zelboraf-to-treat-advanced-melanoma/2458819/The FDA approved Cotellic (cobimetinib) to be used in combination with Zelboraf (vemurafenib) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). Cotellic w
- Lumenis Acquires Pollogen and Expands its Aesthetic Divisionhttps://practicaldermatology.com/news/lumenis-acquires-pollogen-and-expands-its-aesthetic-division/2458827/Lumenis Ltd. completed its acquisition of Pollogen Ltd., an Israeli-based medical aesthetic company that develops and manufactures advanced technologies with full-lines of clinically proven, non-invasive, anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applic
- Zwivel and CareCredit Team Uphttps://practicaldermatology.com/news/zwivel-and-carecredit-team-up/2458836/CareCredit, a provider of patient financing, and Zwivel, an online cosmetic consultation platform that enables cosmetic patients and doctors to interact prior to an in-office consultation, signed a marketing agreement enabling consumers to apply for a CareCredit health, wellness, and beauty credi
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- Fibrocell and Intrexon: Highlights of Pre-Clinical Data for Potential First-in-Class Treatment for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-and-intrexon-highlights-of-pre-clinical-data-for-potential-first-in-class-treatment-for-recessive-dystrophic-epidermolysis-bullosa/2458847/Fibrocell Science, Inc., and Intrexon Corporation are highlighting a poster entitled “Pre-Clinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)” being presented at the American Society of
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- DermTube Offers Video Coverage of NewDerm Live Meetinghttps://practicaldermatology.com/news/dermtube-offers-video-coverage-of-newderm-live-meeting/2458865/NewDerm LIVE, a new meeting for dermatologists just starting out in practice—as well as those not so new to practice—has brought a unique meeting format into the dermatology space. The meeting, supported by the publishers of Practical Dermatology® magazine and NewDerm